5AM Ventures V, L.P. - 02 Nov 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
10%+ Owner
Signature
5AM Ventures V, L.P., By: 5AM Partners V, LLC, its General Partner, By /s/ Scott M. Rocklage, Managing Member
Issuer symbol
TRDA
Transactions as of
02 Nov 2021
Net transactions value
+$5,000,000
Form type
4
Filing time
04 Nov 2021, 21:10:54 UTC
Previous filing
03 Nov 2021
Next filing
02 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Conversion of derivative security +318,616 +96% 649,771 02 Nov 2021 See footnote F1, F2
transaction TRDA Common Stock Conversion of derivative security +2,371,739 +365% 3,021,510 02 Nov 2021 See footnote F1, F2
transaction TRDA Common Stock Conversion of derivative security +564,217 564,217 02 Nov 2021 See footnote F1, F3
transaction TRDA Common Stock Conversion of derivative security +254,512 +8.4% 3,276,022 02 Nov 2021 See footnote F1, F2
transaction TRDA Common Stock Conversion of derivative security +318,140 +56% 882,357 02 Nov 2021 See footnote F1, F3
transaction TRDA Common Stock Purchase $5,000,000 +250,000 +28% $20.00 1,132,357 02 Nov 2021 See footnote

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Series Seed Preferred Stock Conversion of derivative security $0 -2,305,473 -100% $0.000000* 0 02 Nov 2021 Common Stock 318,616 See footnote F1, F2
transaction TRDA Series A Preferred Stock Conversion of derivative security $0 -17,161,644 -100% $0.000000* 0 02 Nov 2021 Common Stock 2,371,739 See footnote F1, F2
transaction TRDA Series A Preferred Stock Conversion of derivative security $0 -4,082,613 -100% $0.000000* 0 02 Nov 2021 Common Stock 564,217 See footnote F1, F3
transaction TRDA Series B Preferred Stock Conversion of derivative security $0 -1,841,620 -100% $0.000000* 0 02 Nov 2021 Common Stock 254,512 See footnote F1, F2
transaction TRDA Series B Preferred Stock Conversion of derivative security $0 -2,302,026 -100% $0.000000* 0 02 Nov 2021 Common Stock 318,140 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.
F2 Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.
F3 Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.